Compare SABR & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABR | ETON |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.9M | 683.7M |
| IPO Year | 2014 | 2018 |
| Metric | SABR | ETON |
|---|---|---|
| Price | $1.59 | $25.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.50 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 5.2M | 465.1K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,866,956,000.00 | $79,950,000.00 |
| Revenue This Year | $7.15 | $40.90 |
| Revenue Next Year | $3.40 | $47.23 |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | 7.46 | ★ 104.94 |
| 52 Week Low | $0.81 | $13.09 |
| 52 Week High | $3.46 | $27.19 |
| Indicator | SABR | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 57.15 | 67.72 |
| Support Level | $1.45 | $16.79 |
| Resistance Level | $1.70 | N/A |
| Average True Range (ATR) | 0.11 | 1.31 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 91.67 | 71.04 |
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.